ABEONA THERAPEUTICS INC.
ABEO · XNASCIK 318306fmd_18E6WVJENCA20GAC02PTGGP5JXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 3 | – | 10 | 3 | 1 | 4 | – | 6 |
| Rental revenue | 2 | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 2 |
| Gross profit | – | – | – | – | – | – | – | – | – | 4 |
| Research and development | 11 | 17 | 39 | 49 | 30 | 39 | 29 | 31 | 34 | 27 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 30 | 65 |
| Total operating expenses | – | 29 | 61 | 77 | 91 | 93 | 52 | 51 | 64 | – |
| Operating income | (24) | (28) | (58) | (77) | (81) | (90) | (51) | (47) | (64) | (89) |
| Interest expense | – | – | – | – | 4 | 4 | 1 | 0 | 4 | 4 |
| Other non-operating income (expense) | 2 | 1 | – | – | – | – | 0 | 3 | 1 | 0 |
| Income before taxes | – | – | – | – | – | – | – | – | (64) | 71 |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | – | – | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | 71 |
| Net income | (22) | (27) | (57) | (76) | (84) | (85) | (40) | (54) | (64) | 71 |
| Net income to common shareholders | (22) | – | – | – | – | (85) | (43) | (54) | (64) | 67 |